NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1052220166

Registered date:12/02/2023

Multicenter, single-blind, randomized controlled trial to evaluate the efficacy of the line-attached sheath-type traction device for endoscopic submucosal dissection in patients with superficail gastric neoplasm.

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedSuperficial gastric neoplasm
Date of first enrollment12/02/2023
Target sample size142
Countries of recruitment
Study typeInterventional
Intervention(s)Intervention group ESD is conducted as following steps: 1) submucosal injection 2)whole circumferential mucosal incision 3)attaching a traction device 4)starting towing 5)submucosal dissection 6)en-bloc resection. Endoscopists pull ( or push) a traction device and change the length of a towing string so as to keep the traction vertical (occasionally, proximal) to the lesion . Conventional ESD (C-ESD) group The C-ESD procedure dose not include the traction method, underwater technique, the pocket creation method, or any other special technique. ESD procedure is dependent on endoscopic knives which endoscopists use. Needle-type knife 1) submucosal injection 2)partial mucosal incision 3)making a mucosal flap 4)partial submucosal dissection5)whole circumferential mucosal incision 6)the completion of submucosal dissection 7)en-bloc resection Insulation-tipped diathermic knife (IT knife) 1) submucosal injection 2)whole circumferential mucosal incision 3)submucosal dissection 4)en-bloc resection Arrangements such as partial submucosal dissection before whole circumferential mucosal incision are permitted.

Outcome(s)

Primary OutcomeProcedure time
Secondary Outcome1) Efficacy-related outcomes (dissecting time, dissection speed, handover rate, en-bloc resection rate, complete en-bloc resection rate, endoscopic curability) 2) Safety-related outcomes (the number of bleeding, adverse events) 3) Device-related outcomes (attachment time, attaching points, the number of devices, the number of slip-off, damage to specimen)

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximumNot applicable
GenderBoth
Include criteria1. Subject who are 18 years of age and more 2. Subject who understand and voluntarily sign an informed consent form. 3. Subjects who have superficial gastric neoplasm meeting the absolute or expanded indication for ESD according to the following Japanese guidelines for gastric treatment (6 edition): i) clinically diagnosed intramucosal cancer (cT1a) representing well differentiated-type adenocarcinoma of any size, without ulcerative findings ii) cT1a representing well-differentiated-type adenocarcinoma, less than 30 mm in size, with ulcerative findings iii) cT1a representing undifferentiated-type adenocarcinoma, less than 20 mm in size, without ulcerative findings. 4. Subject who have computed tomography findings without any suspicious lesions of lymph node metastasis and distant metastasis. 5. Subject who have histological findings of group 4 and 5 according to group classification of gastric biopsy. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2
Exclude criteria1. Subjects who have lesions which is presumed to be difficult in en-bloc resection without a traction device including lesions estimated having severe fibrosis and lesions located in the esophagogastric junction, the fornix, and on the pylorus ring. 2. Subjects have a history of either gastrectomy or reconstructive surgery of the gastric tract. 3. Subjects have either regidual lesion or local reccurence after previous endoscopic treatment. 4. Subjects were registered to this trial for previous lesion. 5. Subjects who were impossible to comply with the cessation of anticoagulant or antiplatelet medications according to japanese guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment and 2017 appendix. 6. Subjects have any hemostasis / coagulation abnormality. 7. Subjects have functional failure in vital organs such as liver, kidney and heart. 8. Subjects were planned to conduct ESD for more than two gastric lesions in the same day. 9. Subjects who are pregnant, suspicious of pregnant and lactating. 10. Subjects who were deemed ineligible for a specific reason.

Related Information

Contact

Public contact
Name Hirofumi Abe
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo Hyogo Japan 650-0017
Telephone +81-78-382-6305
E-mail abe627@med.kobe-u.ac.jp
Affiliation Kobe university hospital
Scientific contact
Name Toshitatsu Takao
Address 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo Hyogo Japan 650-0017
Telephone +81-78-382-6305
E-mail ttakao@med.kobe-u.ac.jp
Affiliation Kobe university hospital